Waiting area in knownwell's clinic in Atlanta
MEET KNOWWELL

Comprehensive, empathetic healthcare — with GLP-1 support*

Insurance accepted
Telehealth available
FDA-approved

GET A WEGOVY® PRESCRIPTION FOR WEIGHT MANAGEMENT

Meet Wegovy®

Prescription weight management medication
15% average reduction in weight after a year
Injectable medication prescribed as part of a personalized care plan.
Insurance accepted
Telehealth available
FDA-approved

Get bias-free weight management with knownwell

Experts in obesity medicine

Comprehensive, empathetic care from clinicians who specialize in weight management

In-network with insurance

We work with major insurance plans to help make your care and prescription as affordable as possible

Prior authorization support

Our dedicated team helps get your Wegovy® prescription covered — so you're not navigating coverage alone

In-person & virtual availability

Available via telehealth nationwide, with in-person clinics in select cities

What you need to know about Wegovy®

WHAT’S ON THIS PAGE

ABOUT WEGOVY®

What is Wegovy®?

Wegovy® is a prescription medication used for weight management. It belongs to a group of medications called GLP-1s, which help regulate appetite by acting on your natural hunger and fullness signals.

By helping you feel satisfied with less food, Wegovy® can support gradual, sustainable changes in eating patterns when used as part of a broader care plan.

Wegovy® is available in both injectable and oral (pill) forms. Your care team will help determine which option fits your health history, preferences, and treatment goals.

How Wegovy® works

We're here to help
What it does in the body

Wegovy® is a GLP-1 receptor agonist. It mimics GLP-1, a naturally occurring hormone released after you eat that helps regulate appetite, blood sugar, and digestion.

By activating GLP-1 receptors in the brain, particularly in areas involved in appetite regulation, Wegovy® helps reduce hunger and increase feelings of fullness. It also slows gastric emptying, meaning food leaves the stomach more gradually, which can help you feel satisfied for longer after meals.

How this leads to results

When appetite signals feel more balanced and cravings are reduced, it can become easier to eat in alignment with your goals. Over time, this supports meaningful, sustained weight loss — especially when combined with nutrition, movement, and ongoing medical care.

Many people may notice
  • Less day‑to‑day hunger
  • Feeling full sooner and staying satisfied longer
  • Fewer food cravings or urges to snack between meals

Wegovy® works the same way in the body whether it’s taken as an injection or a pill. The main difference is how the medication is taken, which your care team can help you decide.

COST & COVERAGE

Is Wegovy® covered by insurance?

Wegovy® can be covered by insurance, but it depends. Many insurance plans offer coverage for Wegovy®, but it varies by plan, employer, and whether weight management medications are included in your benefits.

Insurance approval can also differ based on factors like medical history, required documentation, and whether prior authorization is needed. For example, for people with type 2 diabetes, certain GLP-1s are automatically covered.

Some plans cover one form of Wegovy®, but not another, and coverage rules can change over time. knownwell helps patients navigate this process. Our dedicated authorization team can assist with prior benefit verification and next steps, so you understand your coverage options before moving forward.

How much does Wegovy® cost?

We're here to help
Insurance accepted

With insurance, Wegovy® can cost as little as $0.83 per day ($25 per month) for eligible patients. Actual costs vary based on your plan, benefits, pharmacy, and prescribed dose.

knownwell’s care team helps review your coverage and navigate any required approvals, so you understand your options before starting treatment.

Self-pay option available

If you’re paying without insurance, cash-pay pricing is available through knownwell:

  • Wegovy® pill: starting at $4.97 per day ($149 per month)
  • Injectable Wegovy®: starting at $7.11 per day ($199 per month)

Pricing varies by formulation and dose. Your care team will review costs with you as part of your plan.

As low as $25 per month

With insurance, or qualifying rates or savings programs.Prescribed as part of a personalized medication plan with ongoing support from your knownwell care team.

Get started with knownwell

WHAT TO EXPECT

What results can you expect?

Studies show that Wegovy® can support meaningful weight reduction over time for many people, when used consistently as part of a broader weight management plan.

What the trials show

Clinical trials show people taking the Wegovy® pill lost about 13.6% of their starting body weight, while those using the Wegovy® injection lost about 15% over a similar timeframe, and some lost up to 20%.

Heart health benefits

Wegovy® has also been shown to reduce the risk of serious heart-related problems, like heart attacks and strokes, in adults who already have heart disease and who are overweight.

What you’ll notice first

Changes in appetite and fullness often begin within the first few weeks, with weight changes becoming more noticeable over the following months.

Broader health improvements
  • Lower blood pressure and improvements in cholesterol and triglyceride levels.
  • Improvements in liver fat and markers of metabolic dysfunction in some patients.
  • Reduced inflammation markers associated with cardiometabolic disease.
  • Individual results vary based on factors like dose, consistency, health history, and lifestyle support.

After 1 year...

83%
of knownwell patients lost ≥10% of body weight and 74% of patients lost ≥ 20% of their body weight
97%
of knownwell patients have sustained weight loss
15%
average reduction in body mass

How to get Wegovy® with knownwell

STEP 1

Complete a short questionnaire

Share your health history, goals, and preferences online or in person.

Start knownwell’s questionnaire.
STEP 2

Meet with a healthcare clinician

A knownwell care team member reviews your information and discusses treatment options with you.
STEP 3

Receive a prescription, if appropriate

If Wegovy® is a good fit, your care team will prescribe the medication and outline next steps.
STEP 4

Get your medication

Wegovy® is provided through knownwell, with guidance on how and when to start, plus ongoing support along the way.

A CLOSER LOOK AT WEGOVY®

We're here to help

Frequently asked questions

What side effects should I know about?

Common Wegovy® side effects include nausea, vomiting, diarrhea, constipation, and stomach discomfort, especially when starting or increasing the dose. These often improve over time.

Who should not take Wegovy®?

Wegovy® isn’t appropriate for everyone. Eligibility is impacted by certain medical conditions, a personal or family history of specific thyroid cancers, or certain endocrine disorders. 

Your knownwell care team will review your health history to determine whether Wegovy® is a safe option for you.

How is Wegovy® taken?

Injectable Wegovy® is given as a once-weekly subcutaneous injection, meaning it’s injected just under the skin using a prefilled pen. 

The Wegovy® pill is taken each morning, by mouth with about 4 ounces of water, on an empty stomach, at least 30 minutes before eating, drinking anything else, or taking other medications.

How is Wegovy® stored?

Injectable Wegovy® is stored in the refrigerator until it’s used. The Wegovy® pill is stored at room temperature.

Your knownwell care team will go over proper storage and handling instructions for your prescription.

What should I know about Wegovy® dosing?

Wegovy® is started at a lower dose and increased gradually over time to help the body adjust. 

The dosing schedule and final dose depend on whether Wegovy® is prescribed as a pill or an injection, as well as how your body responds. 

Your knownwell care team will review your specific dosing plan and make adjustments if needed.

Nutrition tips while taking Wegovy®

Studies show that Wegovy® can support meaningful weight reduction over time for many people, when used consistently as part of a broader weight management plan.
Choose balanced, nutrient-rich meals
Focus on whole foods like vegetables, lean proteins, and whole grains to support overall health and make meals feel satisfying.
Hydrate throughout the day.
Drinking water regularly can help with appetite cues and support weight management.
Pay attention to how you feel after meals.
Because Wegovy® can change hunger signals and sometimes cause digestive symptoms, smaller, slower meals can be easier to tolerate early in treatment.
Plan meals around your routine.
Eating when you’re truly hungry and spacing meals evenly can help support appetite regulation as your body adjusts.
These general patterns fit with how Wegovy® works in the body and can help support your treatment goals alongside your care team's guidance.

Explore medication options

We're here to help
Ozempic® The same active ingredient as Wegovy®, delivered as a weekly injection with strong clinical evidence supporting weight loss outcomes of 15–20%.
Zepbound® A dual GLP-1/GIP receptor agonist that targets two appetite-related pathways, with clinical outcomes of 15–23% weight loss.
Qsymia® or Contrave® Daily or twice-daily pill alternatives for those who prefer to avoid injections, with typical outcomes ranging from 5–10% weight loss.
Explore other GLP-1 options.

Ready to see if Wegovy® is right for you?

Meet with a knownwell clinician to review your options, discuss whether Wegovy® fits your needs, and get guidance on next steps. knownwell knows that long-term weight management support is critical. That’s why our patients meet with the same clinician throughout their entire time at knownwell to review options, discuss whether Wegovy® fits their needs, and get guidance on next steps.

SEE CLINIC LOCATIONS

The science of Wegovy®

A closer look at GLP-1 receptor biology, peptide engineering, and metabolic effects

Rooted in your biology

Wegovy® contains semaglutide, a lab-engineered version of a hormone your body already makes called GLP-1 (glucagon-like peptide-1). Your natural GLP-1 breaks down within minutes — semaglutide is designed to stick around much longer.

It's built to resist breakdown in the bloodstream, which extends its effects to a full week. That's what makes once-weekly dosing possible — and why it works differently from older, shorter-acting treatments.

Your brain on Wegovy®

Wegovy® works in the part of your brain that controls hunger. It doesn’t suppress your appetite the way stimulants do, but it turns down the volume on hunger signals.

When it activates those receptors, you feel full sooner, stay satisfied longer, and naturally eat less — without feeling deprived or fighting cravings.

Makes your metabolism work better

Wegovy® only triggers insulin release when your blood sugar is actually elevated — so it works with your body's natural rhythms rather than overriding them. That also means a much lower risk of blood sugar dropping too low, which is a common concern with other diabetes and weight medications.

Beyond blood sugar, it slows digestion, helps your body use insulin more effectively, and reduces fat buildup in places it shouldn't be — like the liver.

The history of GLP-1 medications

1980s - 1990s

Discovery of GLP-1

Scientists first identified glucagon-like peptide-1 (GLP-1) as a naturally occurring hormone released from the gut after eating.
Researchers discovered that GLP-1 helps:
  • Stimulate insulin release
  • Reduce glucagon (a hormone that raises blood sugar)
  • Slow stomach emptying
  • Signal fullness to the brain
This made GLP-1 a promising target for treating type 2 diabetes
 2000s

The Gila Monster Connection

While researching ways to extend GLP-1's lifespan in the body, scientists made a surprising find: Gila monster saliva contains exendin-4, a compound similar to human GLP-1 but far more resistant to breakdown.

In 2005, this led to the first FDA-approved GLP-1 receptor agonist, Exenatide (Byetta®) — lasting long enough, unlike natural GLP-1, to be used therapeutically.
 2010s

Longer-acting GLP-1 Medications

As research advanced, medication modifications became more refined — leading to longer-acting medications like liraglutide (Saxenda®) and semaglutide (Ozempic®, Wegovy®).

Semaglutide is ~94% similar to natural GLP-1 but engineered to resist breakdown, enabling once-weekly dosing with significantly improved outcomes for both blood sugar control and weight management.
2021 - Present

The Small-molecule Breakthrough

In 2021, Wegovy® (semaglutide 2.4 mg) became FDA-approved for chronic weight management. Clinical trials showed average weight loss of about 15% over 68 weeks, with some patients losing 20% or more.

GLP-1 medications are now recognized as a major advancement in obesity medicine, targeting appetite regulation rather than relying solely on willpower or calorie restriction.

Important safety information

We're here to help
Wegovy® is an FDA-approved prescription medication for chronic weight management when used alongside nutrition and lifestyle support. Like all medications, it isn’t right for everyone.
Who should not take Wegovy®
  • People with a personal or family history of medullary thyroid cancer (MTC)
  • People with a rare endocrine condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • Anyone who has had a serious allergic reaction to tirzepatide or the ingredients in Wegovy®

Talk with your provider if you are pregnant, plan to become pregnant or breastfeed, or have a history of:

  • Pancreatitis or gallbladder problems
  • Severe stomach or digestive conditions
  • Kidney disease
  • Vision problems related to diabetes
What to watch for

Some side effects require prompt medical attention, including:

  • Severe or ongoing abdominal pain
  • Signs of an allergic reaction, such as swelling or trouble breathing
  • Symptoms of very low blood sugar, especially if you take diabetes medications

Your knownwell care team will review your health history, medications, and safety considerations before prescribing Wegovy® and will continue to support you throughout treatment.

DISCLAIMERS & SOURCES

Disclaimers

* In clinical trials of the pill, people lost about 13.6% of their body weight over 64 weeks. In trials of the once-weekly Wegovy® injection (semaglutide 2.4 mg), people lost about 15% of their body weight over 68 weeks, and about 1 in 3 patients lost about 20% or more. In a study of patients who took the Wegovy pill daily as directed, they lost 17% body weight (Oasis 4)

Sources

1.
Alzahrani, A. M., Alshobragi, G. A., Alshehri, A. M., et al. (2025). Molecular pharmacology of glucagon-like peptide 1-based therapies in the management of type two diabetes mellitus and obesity. Integrated Pharmacy Research and Practice, 14, 59-72. doi:10.2147/IPRP.S503501. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC11987703/
2.
Barrea, L., Annunziata, G., Verde, L., et al. (2025). A multidisciplinary perspective on semaglutide treatment and medical nutrition therapy in obesity management. Current Obesity Reports, 14(1), 73. doi:10.1007/s13679-025-00667-3. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12549762/
3.
Blundell, J., Finlayson, G., Axelsen, M., et al. (2017). Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism, 19(9), 1242-1251. doi:10.1111/dom.12932. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC5573908/
See all
4.
Chao, A. M., Tronieri, J. S., Amaro, A., et al. (2023). Semaglutide for the treatment of obesity. Trends in Cardiovascular Medicine, 33(3), 159-166. doi:10.1016/j.tcm.2021.12.008. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC9209591/
5.
Davy, B. M. (2025). Water intake, hydration, and weight management: The glass is half full. Obesity, 33(7), 1199-1200. doi:10.1002/oby.24177. Retrieved from https://pubmed.ncbi.nlm.nih.gov/40374025/
6.
Gadde, K. M., Allison, D. B., Ryan, D. H., et al. (2011). Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): A randomised, placebo-controlled, phase 3 trial. The Lancet, 377(9774), 1341-1352. doi:10.1016/S0140-6736(11)60205-5. Retrieved from https://hcp.qsymia.com/efficacy-and-safety/study-conquer/
7.
Garvey, W. T., Frias, J. P., Jastreboff, A. M., et al. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet, 402(10402), 613-626. doi:10.1016/S0140-6736(23)01200-X. Retrieved from https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01200-X/fulltext
8.
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. doi:10.1056/NEJMoa2206038. Retrieved from https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
9.
Mozaffarian, D., Agarwal, M., Aggarwal, M., et al. (2025). Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society. American Journal of Lifestyle Medicine, 19(3). doi:10.1177/15598276251344827. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12125019/
10.
Novo Nordisk Inc. (2026). Wegovy® (semaglutide) savings and support options. Retrieved from https://www.wegovy.com/obesity/what-to-pay-for-wegovy.html
11.
U.S. Food and Drug Administration. (2025). OZEMPIC (semaglutide) injection, for subcutaneous use: Highlights of prescribing information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035,209637s037lbl.pdf
12.
U.S. Food and Drug Administration (2025). WEGOVY (semaglutide) injection, for subcutaneous use; WEGOVY (semaglutide) tablets, for oral use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218316Orig1s000lbl.pdf
13.
Wadden, T. A., Foreyt, J. P., Foster, G. D., et al. (2011). Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: The COR-BMOD trial. Obesity, 19(1), 110-120. doi:10.1038/oby.2010.147. Retrieved from https://pubmed.ncbi.nlm.nih.gov/20559296/
14.
Wharton, S., Lingvay, I., Bogdanski, P., et al. (2025). Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. New England Journal of Medicine, 393(11), 1077-1087. doi:10.1056/NEJMoa2500969. Retrieved from https://www.nejm.org/doi/full/10.1056/NEJMoa2500969
15.
Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. doi:10.1056/NEJMoa2032183. Retrieved from https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
Hallway photo of knownwell's clinic in Atlanta

Ready to see if
GLP-1s are right for you?

Get started with weight management care at knownwell.